FPC employs Niklas Strid as Vice President Customer

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jan 10, 2014 at 2:15 AM

FPC employs Niklas Strid as Vice President Customer Projects

Fingerprint Cards (FPC) has employed Niklas Strid as Vice President Customer Projects and new member of FPC's Executive Management Group. Niklas was previously at ST-Ericsson, as well as Ericsson, where he has held various roles since 2002, most recently as Senior Project Manager for Customer Support. Niklas is highly experienced in the mobile phone industry, and has worked in an international environment for many years, primarily in Korea, with complex systems integration in globally successful mobile phones and tablets from leading OEMs. Niklas Strid will replace Henrik Storm, FPC's current VP Customer Projects, who has decided to seek new challenges in another sector after ten years with FPC. Henrik will continue to serve as an advisor to FPC during 2014 if required. "My ten years with FPC have been very exciting, and being part of a breakthrough for mobile biometrics has been a great experience. I would like to thank everyone I have worked with over these past years, and I am convinced that the industry's powerful growth will continue in the years ahead," says Henrik Storm. FPC's President and CEO, Johan Carlström, says: "With the recruitment of Niklas Strid, FPC has acquired yet another individual whose relevant background, solid understanding of how FPC can meet its customers' needs and requirements, and extensive contact networks in Asia - particularly Korea - will make a direct contribution to FPC's success in both ongoing and future customer projects. Niklas will further boost FPC's efforts to become the leading supplier of fingerprint sensors for the mobile industry." "I would also like to thank Henrik Storm, who has been a great asset to FPC in his various roles, for his dedication, flexibility and technical prowess. Henrik has been a major contributor to FPC's success in recent years and we wish him the best of luck with his future endeavors." For more information contact: Johan Carlström, President and CEO, Fingerprint Cards AB (publ), +46 31-60 78 20, investrel@fingerprints.com About Fingerprint Cards AB (publ) Fingerprint Cards AB (FPC) markets, develops and produces biometric components and technologies that through the analysis and matching of an individual's unique fingerprint verify the person's identity. The technology consists of biometric sensors, processors, algorithms and modules that can be used separately or in combination with each other. The competitive advantages offered by FPC's technology include unique image quality, extreme robustness, low power consumption and complete biometric systems. With these advantages and the ability to achieve extremely low manufacturing costs, the technology can be implemented in volume products such as smart cards and mobile phones, where extremely rigorous demands are placed on such characteristics. FPC's technology can also be used in IT and Internet products for security and access control, etc. Fingerprint Cards AB (FPC) is listed on Nasdaq OMX Stockholm (FING B) and has its head office in Gothenburg, Sweden. Fingerprint Cards AB (publ) discloses this information pursuant to the Swedish Securities Market Act (2007:528) and the Swedish Financial Instruments Trading Act (1991:980). The information was issued for publication on January 10, 2014 at 08:00 a.m. Important information Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the constituent information in accordance with the rules and regulations prevailing in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any of the company's securities in any jurisdiction. [HUG#1753848]

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Fluence Energy Hits Legal Snag: Investors Called to Act

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

D-Wave Investors Must Decide by Dec 15 Class Suit

Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...